| |
Whole cohort (n = 886; 1893 visits)
|
SSc with features of overlap disease (n = 221;628 visits)
|
SSc without features of overlap disease (n = 665; 1265 visits)
|
|---|
|
Parameter
|
Odds ratio (95 % CI)
|
p Value
|
Odds ratio (95 % CI)
|
p Value
|
Odds ratio (95 % CI)
|
p Value
|
|---|
|
Self-reported worsening of cardiopulmonary, vascular or skin symptomsa
|
1.05 (0.57–1.94)
|
0.87
|
1.24 (0.48–3.18)
|
0.66
|
1.03 (0.45–2.35)
|
0.94
|
|
Digital ulcers/necrosisa
|
1.15 (0.84–1.56)
|
0.38
|
1.62 (1.04–2.51)
|
0.034
|
0.82 (0.53–1.27)
|
0.37
|
|
Sclerodermaa
|
0.97 (0.76–1.23)
|
0.78
|
1.08 (0.75–1.58)
|
0.67
|
0.87 (0.63–1.18)
|
0.37
|
|
Tendon friction rubsa
|
1.15 (0.64–2.08)
|
0.64
|
2.31 (1.05–5.10
|
0.037
|
0.54 (0.19–1.53)
|
0.24
|
|
Synovitis/arthritisa
|
0.95 (0.69–1.31)
|
0.76
|
1.18 (0.73–1.91)
|
0.50
|
0.80 (0.51–1.25)
|
0.32
|
|
Modified Rodnan skin score >14a
|
0.98 (0.96–0.99)
|
0.013
|
0.97 (0.95–1.01)
|
0.087
|
0.98 (0.96–1.01)
|
0.16
|
|
Erythrocyte sedimentation rate >30 mm/ha
|
0.98 (0.98–0.99)
|
0.022
|
0.99 (0.99–1.01)
|
0.97
|
0.99 (0.97–0.99)
|
0.026
|
|
DLCO <80 % predicteda
|
0.81 (0.61–1.09)
|
0.17
|
1.14 (0.66–1.96)
|
0.65
|
0.72 (0.51–1.03)
|
0.073
|
|
C-reactive protein >8 mg/La
|
1.01 (0.99–1.01)
|
0.90
|
0.97 (0.93–1.01)
|
0.073
|
1.01 (0.99–1.01)
|
0.41
|
|
BMIb
|
0.91 (0.88–0.94)
|
<0.0005
|
0.90 (0.85–0.95)
|
<0.0005
|
0.91 (0.87–0.95)
|
<0.0005
|
|
FVC <80 % predictedb
|
1.24 (0.78–1.97)
|
0.37
|
2.90 (1.32–6.38)
|
0.0080
|
0.87 (0.47–1.61)
|
0.65
|
-
Abbreviations: BMI Body mass index, FVC forced vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide corrected for haemoglobin
- All variables listed in the table were included in the final multivariable generalised estimating equation model
-
aComponents of European Scleroderma Study Group disease activity index
-
bAdditional disease activity variables entered into multivariable regression model on the basis of significance in univariable analysis
